STOCKS TELEGRAPH

Tag: 22nd Century Group

  • 22nd Century Group (XXII) Witnesses Afterhours Surge With New Contract Signing

    22nd Century Group, Inc. (NASDAQ: XXII) experienced a rollercoaster ride on Thursday’s trading session, initially plummeting over 16% before staging a remarkable afterhours recovery, soaring by an astonishing 77%. This dramatic price movement has captured the attention of investors, with trading volumes nearly sextupling compared to the norm.

    Company’s Profile and Recent Developments

    22nd Century Group, Inc., an American biotechnology company, is focused on tobacco harm reduction and wellness through plant science. Operating across Tobacco and Hemp/Cannabis segments, it manufactures filtered cigars and cigarettes while also delving into bulk ingredient distillate or isolate.

    The recent surge in interest appears linked to a significant new contract manufacturing agreement announced by the company. This deal, set to kickstart revenue generation in the second quarter of 2024, is projected to boost production volumes by over 20%, signaling promising growth prospects.

    Financial Insights and Market Sentiment

    Despite recent positive developments, the company’s financial performance has faced scrutiny. It reported disappointing Q4 and 2020 results, missing revenue and earnings guidelines by significant margins.

    This, coupled with a bearish sentiment surrounding the stock, has contributed to its decline over the past year, from $180 levels to $1 levels. The company has been taking a hammering, with shareholder losing a major chunk of the fair value of their investment in the stock. The recovery of this value seems dim, especially as XXII continues to fail to deliver in its earnings reports as it appears to be doing.

    Conclusion

    In conclusion, 22nd Century Group, Inc. emerges from a tumultuous trading session with a mix of optimism and caution.

    Despite recent setbacks in financial performance and industry challenges, the company’s resilience is evidenced by its strategic contract signings and ongoing market interest. As investors navigate through volatile markets and regulatory uncertainties, the trajectory of XXII remains a focal point, with both challenges and opportunities shaping its journey ahead.

  • 22nd Century Group, Inc. (XXII) Stock Trending Down as Changes to Tobacco Regulation Still Pending

    22nd Century Group, Inc. (XXII) stock prices were down 1.74% as of the market closing on June 15th, 2021, bringing the price per share down to USD$4.52 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock rally by a marginal 1.11%, bringing it up to USD$4.57.

    MTRP Authorization

    The company is allocating efforts towards the securing of Modified Risk Tobacco Product (MRTP) authorization for the company’s proprietary VLN. XXII is confident that its MRTP application submitted to the U.S Food and Drug Administration is in its final stages of review, with no currently outstanding requests for further information or filing.As such the company is poised to capitalize on the commercial launch of its VLN King and VLN Menthol King products, which it will do so within 90 days of securing the MRTP designation. This includes the use of marketing campaigns to raise brand awareness.

    Impending Changes in Nicotine Regulation

    XXII also believes that the FDA is considering implementing a product standard that would require all cigarettes to be minimally or non-addictive. Of course, this sets VLN up to capitalize on the increased market space, given that it already meets that requirement. The company is confident that the paradigm shift in conjunction with the enactment of a nicotine cap will result in favorable market conditions. XXII has reported being ready and willing to license its reduced nicotine tobacco technology to all the cigarette manufacturers hoping to regain compliance with the newly imposed mandate.

    Promising Financial Reports

    Net sales revenue reported for the first quarter of the fiscal year 2021 came in at USD$6.8 million, as compared to the USD$7.1 million reported in the same time period of the prior fiscal year. Gross profits were up to USD$647,000 in Q1 2021, representing a USD$360,000 year-over-year increase. Accordingly, gross profit margins improved by 540 basis points. This represents the fifth consecutive quarter that has seen year-over-year improvements, signaling XXII’s ability to successfully execute its ongoing business plans.

    Stellar Liquidity Position

    XXII reported a strong liquidity position, with USD$30.9 million in cash, cash equivalents, and short-term investment securities as of the end of the first quarter of 2021. This is a massive improvement on the USD$22.3 million reported as of March 31st, 2020. This difference is primarily attributable to the USD$11.8 million generated from the completion of the cash exercise of warrants during February and March of 2021. The company currently has no further warrants outstanding.

    Future Outlook for XXII

    Armed with a solid liquidity position and stellar financial reports, XXII is poised to capitalize on the increasingly likely changes in tobacco regulation. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.